HER2-targeted breast cancer treatments, include monoclonal antibodies (trastuzumab, pertuzumab), tyrosine kinase inhibitors (lapatinib, neratinib), and antibody–drug conjugates (Ado-trastuzumab emtansine [T-DM1]) [12,13,14,15]. This evidence concerns the gene ERBB2 and breast carcinoma.